SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Novo Nordisk CEO Lars Fruergaard Jørgensen
C-suite
UPDATED: With Novo CEO’s Sudden Exit, Analysts Worry ‘There’s Something Pretty Wrong Here’
Over Lars Fruergaard Jørgensen’s eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares have taken a turn since mid-2024, falling by half in one year.
May 16, 2025
 · 
5 min read
 · 
Annalee Armstrong
Vector. Modern backgrounds. Mind Map Team - Illustration
FDA
After FDA Cuts, Planning for Upcoming ODAC Meeting Has Been ‘Absolute Chaos’
As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that volunteers with little training are scrambling to secure the required expertise after workforce cuts decimated the adcomm planning office.
May 15, 2025
 · 
4 min read
 · 
Heather McKenzie
Halftone hands shake coins out of paper money. Modern collage. Concept of inflation, bankruptcy, poverty. Financial difficulties
Deals
Bluebird’s Private Equity Buyout Boosts Upfront Cash for Shareholders
After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has a new deal to offer shareholders.
May 15, 2025
 · 
1 min read
Life is full of challenges and unexpected obstacles. Use these experiences as motivation to keep pushing forward and striving for your goals
Neurodegenerative disease
FDA Delays Decision Date on Biohaven’s Spinocerebellar Ataxia Application
The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
RFK Jr. Firm on HHS Cuts, Wobbles on Measles Vaccine
At a sometimes-contentious U.S. Senate hearing, the Health and Human Services secretary was evasive on the rationale behind cuts being made to the department and his endorsement of the measles vaccine amid a rapidly growing outbreak.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Gentilly, France, March 21, 2021: Exterior view of the Sanofi headquarters building. Sanofi is a French multinational company specializing in the health sector
Manufacturing
Sanofi Hops Aboard US Manufacturing Blitz With $20B Commitment
Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
AbbVie’s Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who have received prior lines of treatment.
May 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Photo of business center in downtown San Francisco at sunset
Now Hiring
10 Companies Hiring in San Francisco
Looking for a biopharma job in San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals like you.
May 15, 2025
 · 
2 min read
 · 
Angela Gabriel
Close the deal by shaking hands. Art collage. Orange circle in the center.
Obesity
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with Septerna to put new discovery-stage programs into play.
May 14, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS